Brought to you by 
Ventana to develop companion test for AEterna’s AEZS108
13 Oct 2016
Executive Summary
In one of two companion diagnostics deals it signed on the same day, Roche Diagnostics Corp.’s Ventana Medical Systems Inc. (tissue analysis) will create a test for oncology drug developer AEterna Zentaris Inc.’s AEZS108 for the immunohistochemical determination of luteinizing hormone-release hormone (LHRH) receptor expression.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Large Molecule
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ventana to develop companion test for AEterna’s AEZS108
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice